Download Files:
RBN-2397
SKU
HY-136174-10 mg
Category Reference compound
Tags Cancer, Cell Cycle/DNA Damage;Epigenetics, PARP
$500 – $2,750
Products Details
Product Description
– RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].
Web ID
– HY-136174
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C20H23F6N7O3
References
– [1]RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency|[2]Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.
CAS Number
– 2381037-82-5
Molecular Weight
– 523.43
Compound Purity
– 99.86
SMILES
– O=C1C(C(F)(F)F)=C(N[C@@H](C)COCCC(N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=O)C=NN1
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 200 mg/mL (ultrasonic)
Target
– PARP
Isoform
– PARP7
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.